ArticleRheumatology (Oxford, England)2022

Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study.

Lyn D Ferguson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.